IgMBRAZOR™ GTx Preclinical Grade
Preclinical grade format of the IgMBRAZOR GTx enzyme for digestion of IgM. This formulation has low levels of endotoxins (<1 EU / vial).
Contact Us
IgMBRAZOR™ GTx Preclinical – Digestion of IgM
IgMBRAZOR is a unique IgM-specific protease that digests human IgM at one specific site below the CH2 domain in the heavy chain, generating homogeneous F(ab’)2 and Fc fragments.
SmartEnzymes™
IgMBRAZOR™ GTx Preclinical Grade is an IgM-specific protease with validated low endotoxin levels, developed for in vivo preclinical research into IgM-mediated disease and immunomodulation. It digests human IgM at a single site in the heavy chain, dismantling the pentameric structure that drives complement activation and avid antigen binding, for rapid reduction of pathogenic IgM in gene therapy, autoimmunity, and transplantation research models.
Why IgMBRAZOR™ GTx Preclinical?
- First-in-class – uniquely enables selective in vivo IgM reduction without disrupting IgG-mediated immunity
- Validated low endotoxin – controlled levels suitable for in vivo preclinical applications
- Broadly applicable – supports in vivo research in gene therapy, autoimmunity, and transplantation
Human IgM
30 min reaction
No need for reducing agents or co-factors
VPDQDT / AIRVFA (in the heavy chain)
Product Formats
About IgMBRAZOR™ GTx Preclinical
IgMBRAZOR GTx Preclinical Grade is a protease that digests human IgM at a single site in the heavy chain, generating a homogeneous pool of F(ab’)2 and Fc fragments that cannot reassemble into functional pentamers. IgM is the only known substrate, which makes IgMBRAZOR GTx suitable for use in complex samples and in vivo.
In vivo IgM cleavage addresses an immune arm that complements IgG-directed approaches. As a pentamer, IgM binds antigen avidly and activates complement potently; selective IgM reduction dismantles these functions without disrupting IgG-mediated protective immunity. Applications range from mitigating complement-driven vector injury in gene therapy to preclinical research in IgM-mediated autoimmunity and antibody-mediated rejection in transplantation.
IgMBRAZOR GTx Preclinical Grade is manufactured with validated and controlled low endotoxin levels, making it suitable for a wide range of in vivo preclinical studies. The enzyme is recombinantly expressed in E. coli. It carries a His-tag and has a molecular weight of 38 kDa.
Resources
Safety Data Sheet
Certificate of Analysis
Find your certificate of analysis »FAQ and Support
There are not yet any FAQ’s for this product. If you have a technical question, please contact us.
Legal & Disclaimers
All rights reserved. Genovis products may be covered by one or more patents, trademarks and copyrights owned by Genovis AB or licensed from third parties. For more information about commercial rights, please contact the Genovis team at licensing@genovis.com.
Genovis products are intended for research use only. They are not intended to be used for therapeutic or diagnostic purposes in humans or animals. All goods and services are sold subject to Genovis’ General Terms and Conditions of Sale.
© Genovis AB